TREC screening results: understanding false positives in newborns

The Mechanics of TREC Quantification in Dried Blood Spots

Their quantification forms the molecular foundation of population-level newborn screening for Severe Combined Immunodeficiency (SCID) and broader T-cell lymphopenias. The assay detects these circular DNA fragments using real-time quantitative PCR (qPCR) amplified from dried blood spot (DBS) samples collected on standard newborn screening cards, typically obtained via heel-stick between 24 and 72 hours of life.

The biological rationale is straightforward: TRECs are produced only during successful intrathymic T-cell maturation. Infants with profoundly impaired thymic output—whether due to a primary genetic defect in lymphocyte development or, secondarily, to conditions that suppress normal T-cell proliferation—will generate fewer TRECs. This relationship translates into a screening biomarker whose concentration serves as a proxy for recent thymic emigrant numbers.

Laboratory practice typically employs a multiplex qPCR format targeting the δRec-ψJα TREC signal joint, often co-amplified with a reference gene (β-actin or RNase P) to control for DNA input. Result reporting uses absolute copy number per microliter of blood or per 3.2 mm DBS punch. Consensus laboratory thresholds for a normal result generally fall above 30–40 copies/μL, though specific cut-offs vary by jurisdiction. A documented protocol example from a Swiss reference laboratory sets the abnormal boundary at fewer than 10 TREC copies per punch. This heterogeneity in cut-offs is itself a structural limitation of cross-jurisdictional data interpretation.

A single low TREC value is a screening signal, not a diagnosis. The assay flags risk; clinical immunology confirms or dismisses it.

Navigating the Positive Predictive Value Gap in SCID Screening

The analytical sensitivity of TREC-based screening for SCID is high, with population-level detection rates consistently exceeding 90% in prospective cohorts. Specificity, however, is the limiting assay metric. Reported positive predictive values (PPV) for SCID specifically range from 0.8% to 11.2% across published screening programs. This narrow band reflects the low prevalence of SCID in the general newborn population—approximately 1 in 50,000 to 1 in 100,000 live births—combined with the breadth of non-SCID conditions that produce overlapping molecular signatures.

When the screening end-point is broadened to include any T-cell lymphopenia, PPV rises dramatically, with reported ranges between 18.3% and 81%. This range itself is informative: the assay's clinical yield depends entirely on how the program defines an actionable abnormal result. Programs with strict copy-number thresholds will capture fewer false positives but risk missing atypical SCID presentations, while permissive thresholds increase sensitivity at the cost of confirmatory workload.

Overall false-positive rates for the TREC assay are reported below 1%, but this aggregate figure obscures important categorical distinctions. False positives in this context are not random laboratory errors—they are biologically driven signals from infants whose T-cell output is transiently or secondarily reduced. This distinction has direct implications for clinical communication: a "false-positive" TREC result is rarely a technical artifact and often a genuine signal of altered lymphocyte dynamics that warrants immunological evaluation regardless of the eventual SCID diagnosis.

Physiological and Secondary Drivers of Low TREC Levels

A substantial proportion of abnormal TREC results originate from physiological immaturity or secondary, non-genetic suppression of T-cell output rather than primary immunodeficiency. These drivers account for the majority of non-SCID abnormal screens and represent the principal interpretive challenge facing confirmatory immunologists.

Prematurity is the dominant confounder. Preterm infants exhibit reduced thymic output relative to term counterparts, and their TREC copy numbers may fall below screening thresholds based solely on gestational age. In many protocols, repeat screening at corrected gestational age 37 weeks is recommended before escalation to invasive diagnostic procedures. This approach leverages the natural trajectory of thymic maturation: TREC levels in premature infants frequently normalize as the infant reaches term-equivalent developmental milestones.

Secondary T-cell lymphopenias from non-genetic causes further inflate the false-positive burden. Documented contributors include:

• Prenatal or perinatal corticosteroid exposure
• Neonatal abstinence syndrome
• Congenital cardiac anomalies, particularly those with associated lymphatic or thymic hypoplasia
• Gastrointestinal malformations, including intestinal atresias
• DiGeorge syndrome (22q11.2 deletion)
• CHARGE syndrome
• Ataxia-telangiectasia

Each of these conditions can suppress TREC generation through mechanisms ranging from direct thymic injury to systemic stress-induced lymphopenia. Distinguishing these secondary causes from primary immunodeficiency requires integration of the TREC value with clinical examination, perinatal history, and targeted confirmatory testing.

Prematurity alone can suppress TREC output below threshold. Resampling at corrected gestational age is a standard, evidence-supported reflex.

Clinical Pathways for Abnormal Results: From Repeat Testing to Flow Cytometry

The management algorithm following an abnormal TREC result is protocol-driven, with urgency calibrated to the absolute copy number. Results at or near zero TREC copies are categorized as urgent positives and mandate immediate referral to a clinical immunologist, with parallel notification of a transplant center if SCID remains in the differential. Lesser reductions in copy number typically trigger a repeat dried blood spot test before invasive workup.

Confirmatory evaluation centers on flow cytometry, which enumerates lymphocyte subsets and quantifies autologous T-cell numbers. The standard laboratory criterion for a SCID-compatible immunological phenotype is fewer than 300 autologous T cells per microliter of blood. This threshold, combined with absent naïve T-cell markers and absent T-cell receptor excision circle signal, establishes the functional immunodeficiency before genetic sequencing is pursued.

Genetic testing follows two principal architectures: targeted panel sequencing for known SCID-associated genes (IL2RG, JAK3, RAG1, RAG2, ADA, IL7R, among others) or whole exome sequencing (WES) when the phenotype is ambiguous or syndromic features are present. Targeted panels offer higher throughput and lower cost but may miss novel pathogenic variants; WES provides broader coverage at the expense of longer turnaround and increased variant interpretation complexity. The choice between architectures depends on institutional resources, clinical urgency, and the presence or absence of distinguishing phenotypic features.

Adjunctive assays may include measurement of adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) enzyme activity to exclude metabolic causes of lymphopenia, as well as K-deleting recombination excision circle (KREC) quantification when B-cell lineage defects such as X-linked agammaglobulinemia are suspected. TREC assays do not detect B-cell deficiencies; KREC analysis is required for that domain.

Distinguishing Primary Immunodeficiency from Transient Thymic Immaturity

The final interpretive step is differential classification: whether the abnormal TREC result reflects a permanent genetic lesion in lymphocyte development or a transient physiological state. Three diagnostic anchors guide this determination.

First, trajectory. Repeat TREC measurement after a defined interval demonstrates whether copy numbers are rising, stable, or falling. A rising trajectory in a preterm infant typically indicates resolving thymic immaturity; a persistently low or declining trajectory suggests a fixed deficit.

Second, lymphocyte phenotype. Flow cytometry distinguishes naïve from memory T-cell populations. Infants with primary SCID show profound depletion of naïve T cells; secondary or transient lymphopenias preserve naïve populations, though at reduced absolute counts. The naïve T-cell fraction is therefore a higher-resolution marker than absolute CD3+ count alone.

Third, genetic confirmation. Pathogenic variants in known SCID genes, identified through panel sequencing or WES, establish a definitive primary immunodeficiency diagnosis. The absence of such variants, combined with normalizing TREC values and intact naïve T-cell populations, supports classification as transient thymic immaturity or secondary lymphopenia.

The clinical utility of TREC screening therefore depends not on the screening result itself but on the structured confirmatory pathway it activates. Programs that integrate reflex repeat testing, rapid-access flow cytometry, and tiered genetic sequencing achieve the highest diagnostic accuracy while minimizing unnecessary invasive procedures in infants whose low TREC values reflect developmental stage rather than disease.

Low TREC copy numbers stratify risk. Confirmatory flow cytometry and genetic sequencing resolve the differential.

The TREC assay is a high-sensitivity population filter, not a diagnostic test. Its value emerges from the downstream infrastructure that interprets its results—laboratories capable of quantitative flow cytometry, clinical immunologists trained in primary immunodeficiency, and genetic sequencing pipelines with curated SCID gene panels. Programs lacking these confirmatory resources face elevated rates of diagnostic delay and unnecessary intervention, regardless of the screening assay's analytical performance. The PPV gap between 0.8% and 11.2% for SCID specifically is not an assay failure; it is a reflection of disease prevalence and the breadth of the differential that confirmatory immunology must resolve.